🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

The sexually transmitted infection are on the rise around the world, with estimates suggesting in excess of 82 million new cases each year. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the context of rising global incidence, escalating drug resistance and the extremely scarce available drugs at this time.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This milestone marks a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Data and Worldwide Availability

Based on results published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This establishes an comparable level with the typical regimen, which uses a dual-drug approach. The research involved hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in many developing nations.

Doctors on the front lines have shared optimism. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for managing the epidemic. This is considered essential to lessen the impact of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.